Processa Pharmaceuticals (NASDAQ:PCSA) Price Target Cut to $4.00 by Analysts at Benchmark

Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price target decreased by Benchmark from $9.00 to $4.00 in a research report released on Tuesday morning, Benzinga reports. Benchmark currently has a speculative buy rating on the stock. A number of other analysts have also recently issued reports on PCSA. Oppenheimer cut their price objective on […]

Related Keywords

Patrick Lin ,David Young ,Processa Pharmaceuticals ,Maxim Group ,Renaissance Technologies ,Dimensional Fund Advisors ,Processa Pharmaceuticals Inc ,Processa Pharmaceuticals Company Profile ,Processa Pharmaceuticals Price Performance ,Institutional Investors Weigh In On Processa Pharmaceuticals ,News Ratings For Processa Pharmaceuticals Daily ,Raymond James Financial Services Advisors Inc ,Get Rating ,Fund Advisors ,Raymond James Financial Services Advisors ,Processa Pharmaceuticals Daily ,Nasdaq Pcsa ,Hpcsa ,Medical ,Lower Price Target ,Benchmark Co ,